Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hadn't been there for a bunch of years either - started popping in again now and then as the traffic on Yahoo!'s boards is a bit higher than here and "sometimes" it's a bit entertaining.
It's still mostly a cesspool of insults, rampant lies and misinformation though. That's not changed at all.
I haven't been over there in years.
“While we are keenly focused on continued enrollment in our Phase 3 trial of exebacase and the upcoming interim futility analysis from the study, we continue to amass evidence of the potential utility of exebacase against antibiotic resistant staphylococcus infections in a variety of clinical contexts,” commented Roger Pomerantz, M.D., ContraFect’s Chairman, CEO and President. “And together with our presentations at ECCMID earlier this year, these data further underpin the foundation of our direct lysin agent platform, and the potential for these agents to provide patients with meaningful improvements in clinical outcomes of antibiotic resistant infections.”
https://finance.yahoo.com/news/presentations-asm-microbe-conference-demonstrate-113000599.html
Potential continues to grow here imo.
Chatter on the Yahoo! board for Contrafect is that 'some' of the folks there think that the company is going to talk about the 60% Phase III readout for superiority over the SOC antibiotic course sometime this week or next.
I suspect that is why we are seeing the trends here this last few trading days.
HDG,
Super Tuesday July for stocks I would like to have that as a tradition . Otherwise only Super Tuesday that I know of is the following. And it does not occur in July and not about stocks.
https://en.m.wikipedia.org/wiki/Super_Tuesday
Regards,
Spiky
s-
April 4, 2022: "We currently anticipate results from the interim futility analysis in the first half of 2022."
May 16, 2022: "we have eclipsed the enrollment threshold, meaning over 60% of the methicillin-resistant Staph aureus (MRSA) patients, needed for the interim futility analysis of our Phase 3 DISRUPT study to be conducted and we currently have about two-thirds of the entire study population enrolled as well" ... "We expect this to occur during the first week of July"
Analysis is ongoing since (as the latest) May 30 (May 16 + 14 days) ... but more likely started earlier, since app. 66% was enrolled by May 16.
Anytime ... and not later than July 15. Does Super Tuesday exist in July?
Best,
G
HDG,
LSVT-1701 a lysin from Roivant entering phase 2 clinical trials has been terminated for strategic reasons according to Roivant quarterly update.
Regards,
Spiky
s-
Nope, but:
(i) I expect the result later than July 5
(ii) That could be (more likely) a hedge
Best,
G
HDG,
Have you been following the July 2.5 Puts? It has 23K open interest vs 7K open interest on the July 5 Calls.
Regards,
Spiky
I added to my stash of shares this morning at about $3.29. :D
Looking good and if they get a good preliminary readout this summer - this could easily go a lot higher. There's a lot of potential for an 'antibiotic' treatment that is good against MRSA bacteria.
s-
FYI: I am in.
Best,
G
Analyst
Target Price
Stock Rating
Action
Latest Report
News
TipRanks Analyst Ratings Sorted by date: ascending
analyst
Stephen Brozak
WBB Securities
StarStarStarStarStar
target
$7.00
ranking
Buy
analystAction
Upgraded
date
15 days ago
articletooltip
Click this button to read the definition of [object Object]
analyst
Vamil Divan
Mizuho Securities
StarStarStarStarStar
target
$9.00
ranking
Buy
analystAction
Reiterated
date
a month ago
articletooltip
Click this button to read the definition of [object Object]
analyst
Roanna Ruiz
SVB Securities
StarStarStarStarStar
target
$9.00
ranking
Buy
analystAction
Reiterated
date
a month ago
articletooltip
Click this button to read the definition of [object Object]
analyst
Jason McCarthy
Maxim Group
StarStarStarStarStar
target
$9.00
ranking
Buy
analystAction
Reiterated
date
a month ago
articletooltip
Click this button to read the definition of [object Object]
analyst
Louise Chen
Cantor Fitzgerald
StarStarStarStarStar
target
--
ranking
Buy
analystAction
Reiterated
date
a month ago
article
Overall...
9 out of 10
Outperform
Watching this dip very carerfully. And taking advantage if it lets me.
HDG,
Thank you for your insight. Good luck on your trades.
Regards,
Spiky
s-
What are you expecting the market cap to be on a go futility result?
You still plan to add before futility or after?
HDG,
I do agree that the the recent events is suspicious. My read on Pomerantz is he is very cautious and that he might consider a raise before futility results. I did the following gamble in case this event might happen.
I picked up some July 5 call options a few weeks ago. They were sitting at .20-.30 cents. It was weird that the IV on the July options were so small considering that futility in July was a known event. In the last week the options for July 2.5 puts had a massive bet for 6k at .50. The July calls started trending up a few days after these trades. And the last day or two the July calls shot through the roof.
If dilution happens before futility I would suspect the price to be brought around 6-7 and then sell at a lower price as what happened back in 2021. What are you expecting the market cap to be on a go futility result? You still plan to add before futility or after?
Regards,
Spiky
s-
The recent, significant increase is a little bit suspicious* for me ... I saw the same in several case - immediately - before dilution.
* I think it was a little bit too early ... and too big for July news.
Best,
G
HDG,
I made an entry around the $3 pricepoint. I have been looking at the BARDA cost/shared grant announced in March 2021.
https://www.sec.gov/Archives/edgar/data/1478069/000119312521078756/d122568dex101.htm
There are 6 line items of funding (CLIN0001 ... CLIN0006). CLIN0001 was 9.8mil/31mil (barda/contrafect share) announced back in March 2021. CLIN0002 ... CLIN0006 are options for the Government with certain milestones, which are not known. The total of CLIN0002 ... CLIN0006 is 87mil/84mil (barda/contrafect share). The $ breakdown for CLIN0002 ... CLIN0006 is not known. CLIN0006 is the only funding that does not have a contrafect share.
What i am trying to guess at is how much dilution and when the dilution will happen considering the BARDA grant that might come in? Afterall the futility GO/NO-GO result is a big milestone which hopefully should trigger items of funding.
Regards,
Spiky
s-
As the interim analysis is coming (July 2022) I start to dig ... more is necessary but the first thought (after a short / 1 hour DD): I guess they will raise cash based on the interim announcement.
I will make a more deeper, prudent DD ... but looks like I will jump in before the end of June ... before 26 June.
Best,
G
Assuming the data in this Phase III hold up to what was seen for the subset of patients from the Phase II that the company is now targeting - 2023 could be a big year. The end of 2022 could be kind of fun as well.
HDG,
I would like to hear your thoughts once you get caught up in CFRX. As of last week (last earnings release) 2/3 of patients have now been enrolled. Futility results is expected in the first week of July. I have not been able to find the internal details of the Barda Grant.
When do you plan on jumping in?
Regards,
Spiky
s-
I have a huge backlog (have to "clean out" my "ticker collection") so I am not up-to-date re. CFRX.
Best,
G
HDGabor,
What are your thoughts on dilution? Will Contrafect rely on Barda funding to get them through exebacse approval or will Contrafect raise after interim results? My read on Dr. Pomerantz is he is conservative enough to want money in hand to get the rest of the products into clinical trials. Your thoughts is very much appreciated.
Regards,
Spiky
HDG,
What are your thoughts on dilution? Will Contrafect rely on Barda funding to get them through exebacse approval or will Contrafect raise after interim results? My read on Dr. Pomerantz is he is conservative enough to want money in hand to get the rest of the products into clinical trials. Your thoughts is very much appreciated.
Regards,
S
Thinking $10 - $14 not too far in the future.
Solid.
https://invest.ameritrade.com/grid/p/site#r=jPage/https://research.ameritrade.com/grid/wwws/research/stocks/news/article?c_name=invest_VENDOR&docKey=1952-274af656fd05d750ed210b8378cbb5bb-27%20Apr%202022
Like the way this is trading. Slow and steady
Definitely a lot less quiet of a trading day today,.... nice 20% rise is always good to see.
XBI taking another beating.
Waiting to see where I'll be reloading. One of these swings (hopefully) will leave m in the dust. But my core position will be ready!!!
$2.40's???
has been beaten so bad these last months. A rip in all biotech around. I hope there is more to it but think just a little relief rally.
Needs to hold tomorrow to be real.
Are part of Russell index or something like that. Maybe rebalancing?
Didn't see anything either. They've been seeing some decent news. Keep an eye out for institutional buying filings.
IMO, that time of year.
Couldn't resist the swing though, FER SURE!
$$$$
Interesting upswing today - anybody hear anything newsworthy? I can find anything in my usual places that I look.
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis
Source: GlobeNewswire Inc.?
ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that it has received an additional award from the Cystic Fibrosis Foundation (CFF). This contract award will support investigation of the potential utility of exebacase for treating serious lung infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis (CF). The program, titled Nonclinical Assessment of Lysin Exebacase for Treating MRSA Infections in CF will, over the course of 12 months, evaluate the in vitro activity of exebacase against bacterial specimens obtained from CF patients.
“MRSA lung infections lead to potential acceleration in the decline in lung function and are an independent predictor of mortality in the CF population. Eradication of persistent MRSA in the lungs of CF patients remains a major challenge despite current antibiotic therapy. Thus, there is a pressing unmet need for new medical modalities and novel therapeutic approaches to address the serious health threat to CF patients,” said Cara Cassino, M.D., Executive Vice President of Research & Development and Chief Medical Officer of ContraFect. “We are pleased to have the opportunity to work with the CF Foundation again in order to evaluate the potential utility of exebacase as such a treatment for MRSA lung infections in this vulnerable population,” continued Dr. Cassino.
Pathogenic bacteria are known to be a major contributor to CF disease. The lungs of CF patients are typically colonized with pathogenic bacteria, that damage the epithelial surfaces. The growth of highly resistant Staph aureus or Pseudomonas aeruginosa, two of the most common causes of lung infections in CF patients, is associated with further epithelial surface damage, and potentially an overall decline in pulmonary function. MRSA has become more prevalent in the CF population in recent years, increasing from 9.2 percent in 2002 to 25.9 percent in 2017. MRSA plays a role in pulmonary exacerbations of CF that may require hospitalization and treatment with systemic antibiotics. Chronic lung infections are known to be the main cause of lung function deterioration, and ultimately mortality, in CF patients.
The award from the Cystic Fibrosis Foundation will provide ContraFect with financial support for research activities. Further financial details were not disclosed. ContraFect retains global rights for exebacase and its entire DLA therapeutic pipeline.
I think it's excellent and shows excellent potential. Todays price action is very interesting as well. I wasn't really expecting anything in this sector until after the New Year. The chart shows this right at the short term trend line resistance. 2 trading days left till Christmas break! Enjoy and be safe! A close 2.80 or better Thursday and it's game on imo.
Very cool. Thanks for posting and sharing this.
Very interesting. Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases
ContraFect Corporation
Mon, December 20, 2021, 6:00 AM·8 min read
In this article:
CFRX
-3.20%
Data from Single Pediatric Patient Highlights that FDA-Designated Breakthrough Therapy Exebacase May be a Beneficial Adjunctive Therapy for Severe MRSA Infections in Children
YONKERS, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the recent publication of a case study report highlighting the potential of its first investigational direct lytic agent, exebacase, to treat methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in a pediatric population. The case report was published in the peer-reviewed Clinical Infectious Diseases, a journal of the Infectious Disease Society of America (IDSA).
“These data, although representing a single pediatric patient, provide a compelling case for further evaluation of exebacase in pediatric populations. These findings are especially important given the limited treatment options available to help address these life-threatening infections,” stated Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development of ContraFect Corporation. “We were pleased to learn of the positive outcome of this patient and we will continue to progress our critically important therapeutics as rapidly but as safely as possible.”
The results, published ahead-of-print, describe the pharmacokinetics (PK) and dosing of the first infant to receive exebacase. The patient, a previously healthy 5-month-old male infant, presented to Duke University Hospital for evaluation of jerking movements and inability to sit independently. Following a full evaluation, it was determined that he had a culture confirmed life-threatening MRSA infection with multi-organ involvement, included a left temporal subdural empyema, a retropharyngeal abscess, and right-sided endocarditis. Despite targeted therapy, optimized dosing, and attempts at source control, clearance of bacteremia and clinical improvement was not achieved with standard of care (SOC) antibiotics alone. The treating physician obtained authorization from the U.S. Food and Drug Administration (FDA) to use exebacase under an emergency individual patient investigational new drug application and the patient subsequently received one 3 mg dose of exebacase on hospital day 7. The patient continued to receive SOC anti-staphylococcal antibiotics throughout the hospital stay. Blood cultures became sterile on hospital day 12. The patient had ongoing clinical improvement and serial echocardiograms noted no evidence of heart valve vegetation on hospital day 40. The patient was discharged, without the need for additional surgery.
This report represents a single patient, and it is difficult to know with certainty if clinical improvement was due to exebacase directly, extended SOC antibiotic therapy or the combined effect of both. Nevertheless, exebacase is a novel DLA that may be a beneficial adjunctive therapy for MRSA bacteremia including right-sided endocarditis in children. Future clinical trials are planned to confirm dosing and efficacy in the pediatric population.
About Methicillin-Resistant Staphylococcus aureus (MRSA):
MRSA is a result of Staph aureus infections that are difficult to treat because of bacterial resistance to SOC antibiotics. MRSA bacteremia in particular causes significant morbidity and mortality. Treatment with SOC antibiotics alone is difficult due to increasing virulence, limited drug penetration, adverse events, and increasing resistance. New therapies for MRSA bacteremia are greatly needed.
About Exebacase (CF-301):
Exebacase is an anti-staphylococcal recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections (BSIs) also known as bacteremia. It is the first lysin to enter clinical studies in the U.S. and was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.
Exebacase is currently being studied in the Phase 3 DISRUPT superiority design study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis. In the Company’s Phase 2 study of exebacase, a pre-specified analysis of MRSA-infected patients showed that the clinical responder rate at Day 14 in patients treated with exebacase was nearly 43-percentage points higher than in patients treated with SOC antibiotics alone (74.1% for patients treated with exebacase compared to 31.3% for patients treated with SOC antibiotics alone (p=0.010)). In addition to the higher rate of clinical response, MRSA-infected patients treated with exebacase showed a 21-percentage point reduction in 30-day all-cause mortality (p=0.056), a four-day lower median length of hospital stay and meaningful reductions in hospital readmission rates.
Exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia. Exebacase was licensed from The Rockefeller University and is being developed at ContraFect.
About ContraFect
ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.
Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.
Forward-Looking Statements
This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: the potential for exebacase to treat MRSA bacteremia in pediatric populations, ContraFect’s ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, statements regarding exebacase and clinical improvement, whether exebacase may be a beneficial adjunctive therapy, planned pediatric clinical trials, whether MRSA bacteremia causes significant morbidity and mortality, whether exebacase has the potential to be a first-in-class treatment for Staph aureus bacteremia, whether ContraFect will address life-threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect’s lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect’s product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection and other important risks detailed under the caption “Risk Factors” in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contacts:
Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
Email: mmessinger@contrafect.com
Media:
Jules Abraham
CORE IR
Tel: 917-885-7378
Email: Julesa@coreir.com
Filled 2.68 & another batch @ 2.70. The chart does not appeal to me, I'll say that.
The "end of year discounts". With a low at $3 it's still a lower low. But worth a nibble imo.
Good luck!
I snagged some this morning at about $3.14. Just a few more to sit on while we are waiting for the Phase III results.
Weekly chart says go for it. Daily says, ehhhhh. I'll take a few here though.
Watching ContraFect Shares; Zacks Small-Cap Research Sets $23 Valuation
10:07 am ET November 30, 2021 (Benzinga) Print
Latest Ratings for CFRX DateFirmActionFromTo
Sep 2021SVB LeerinkInitiates Coverage OnOutperform Mar 2021WBB SecuritiesInitiates Coverage OnSpeculative Buy Jun 2020Cantor FitzgeraldInitiates Coverage OnOverweight
View More Analyst Ratings for CFRX
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The company had nothing to do with the $23 valuation.
If I had that answer this would probably be the only bio stock in my portfolio.
Thinking they'll see at least $7 - $10 in 2022. 2nd half.
Not that I disagree with this sentiment - but what's their current reasoning and what's their timeline to reach that value?
Zacks Small-Cap Research Sets $23 Valuation
Whats going on with the rapid activity in CFRX ?? Did they find a cure for global warming or something ??
Looks like there are some trailing stops set, MM's munching them up.
$23 valuation. Don't know about that but sure would love to see it!!
Followers
|
46
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
580
|
Created
|
03/15/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |